Company: LGN
Filing Date: 2025-05-14
Form Type: DRS/A
Source: 0000950123-25-005247
Chunk: 135

Company: Legence Corp.
Filing Date: 2025-05-14
Form: DRS/A
Chunk 135
---
 $    | 1,616,310 |
| Book-to-bill                  
 ratio                         |     |                    |       1.5 |     |      |       1.0 |     |      |       1.5 |
| Total                         |     |                    |           |     |      |           |     |      |           |
| Backlog                       |     | $                  | 1,037,986 |     | $    | 1,308,284 |     | $    | 1,729,800 |
| Awarded contracts             |     |                    |   448,971 |     |      |   395,509 |     |      |   742,294 |
| Backlog and awarded contracts |     | $                  | 1,486,957 |     | $    | 1,703,793 |     | $    | 2,472,094 |
| Book-to-bill                  
 ratio                         |     |                    |       1.4 |     |      |       1.1 |     |      |       1.3 |

The increases in backlog and awarded contracts from December 31, 2023 to December 31, 2024 were primarily attributable to multiple new project awards. The increase in Engineering & Consulting was primarily driven by new projects within the education client end market and additional backlog and awarded contracts from the acquisition of P2S and AMA. The increase in Installation & Maintenance was primarily driven by new projects within the life sciences & healthcare and data centers & technology client end markets. Liquidity and Capital Resources Overview As of December 31, 2024, our primary sources of liquidity included cash and cash equivalents of $81.2 million, $84.8 million available to be borrowed under the Revolving Credit Facility and cash flows from operations. Following the completion of this offering, we expect our primary sources of liquidity to be cash flows from operations, borrowings incurred under our Revolving Credit Facility or proceeds from offerings of debt or equity securities. Access to additional liquidity, such as an increase in the capacity under our existing Revolving Credit Facility or a new financing arrangement, will be subject to our credit ratings and future financial position. 92

Confidential Treatment Requested by Legence Corp. Pursuant to 17 C.F.R. Section 200.83 To date, our primary uses of capital have included funding working capital, capital expenditures for equipment used in our business, acquisitions and refinancing or repayment of debt